Diane Lee BSc (Cardiff), PhD (London)

Research Associate

Clinical Trials Research Unit, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA

Tel: (+44) (0)114 222 0843
Fax: (+44) (0)114 222 0870

email : d.lee@sheffield.ac.uk

Biography

Prior to joining CTRU I worked for a commercial Contract Research Organisation as a Clinical Research Associate in this role my responsibilities were:

• Set up and monitoring of a Phase I oncology study (including site initiations and routine monitoring visits; SDV, writing monitoring reports and follow up letters)
• Set up of a phase III oncology study
• Complete responsibility for an asthma medical device study (including ethics and R&D submissions, site initiation and routine monitoring visits and close out visits)
• Close out visits for a dermatology device study
• Review and QC of monitoring SOPs
• Working closely with sponsor companies to deliver projects on time
• Writing patient information sheets and other study documentation

Previously I have also worked for a major Danish pharmaceutical company and held lab based post doctoral positions.

I joined the University in January 2009 as a Trials Co-ordinator, on the REEACT Trial. My role has expanded to include helping to develop a quality assurance function for the Clinical Trials Research Unit.
I am currently Trial Co-ordinator and Quality Assurance Manager

Research interests

Clinical Research Methodology

Professional activities

Member of the Clinical Research Association
Member of the British Association for Quality Assurance
(Level 1 auditor)

Current projects

• REEACT Trial

Key publications

• Lee DR, Helps SC, Macardle PJ, Nilsson M, Sims NR. Alterations in membrane
  potential in mitochondria isolated from brain subregions during focal cerebral
  ischemia and early reperfusion: evaluation using flow cytometry. Neurochem Res.
  2009 Oct;34(10):1857-66.
• Lee DR, Helps SC, Gibbins IL, Nilsson M, Sims NR. Losses of NG2 and NeuN
  immunoreactivity but not astrocytic markers during early reperfusion following
  severe focal cerebral ischemia. Brain Res. 2003 Nov 7;989(2):221-30.
• Goddard DR, Berry M, Kirvell SL, Butt AM. Fibroblast growth factor-2 induces
  astroglial and microglial reactivity in vivo. J Anat. 2002 Jan;200(Pt 1):57-67
• Goddard DR, Berry M, Kirvell SL, Butt AM. Fibroblast growth factor-2 inhibits
  myelin production by oligodendrocytes in vivo. Mol Cell Neurosci. 2001
  Nov;18(5):557-69.
• Goddard DR, Bunning RA, Woodroofe MN. Astrocyte and endothelial cell
  expression of ADAM 17 (TACE) in adult human CNS. Glia. 2001 Jun;34(4):267-71.
• Goddard DR, Berry M, Butt AM. In vivo actions of fibroblast growth factor-2
  and insulin-like growth factor-I on oligodendrocyte development and myelination
  in the central nervous system. J Neurosci Res. 1999 Jul 1;57(1):74-85.